shareholder proposal (advisory) · 2014
Michael Weinstein, an individual shareholder at Gilead Sciences
Adopt a policy that incentive compensation for the chief executive officer include non-financial measures based on patient access to Gilead's medicines, reducing that compensation where funding cuts, restrictions or formulary placement stop eligible patients obtaining prescribed medicines.
What happened
Result: Not approved at the 7 May 2014 annual meeting as Proposal 7: 26,726,195 for, 1,048,057,432 against, 157,155,528 abstaining and 115,351,928 broker non-votes, which is 2.5 percent of the votes cast for and against.
Gilead's board answered that patient access was already one of many non-financial goals in its executive compensation programme and that the compensation committee needed flexibility to set objectives each year, and we found no change to Gilead's executive compensation structure documented in the pages we opened.
Gilead Sciences, Inc. Shareholders Decimate Plan To Tie CEO Compensation To Drug Access, BioSpace
Who is involved
- Michael Weinstein, an individual shareholder filer, not an organization we hold yet
- Gilead Sciences company
What this campaign is about
- Right to share in cultural life and in scientific advancement and its benefits; protection of authors' moral and material interests Pivotal · Universal Declaration of Human Rights